Key result
ACS is linked to ~2.4-fold higher platelet P2Y12 mRNA expression compared to healthy controls.
Why the study?
Platelet hyperactivity in ACS is well-documented, but research into the molecular basis of phenotypic changes in platelet functionality remains limited.
Does acute coronary syndrome alter the expression and protein concentration of platelet surface receptors such as P2Y12 compared to healthy controls?
Case-Control
Does acute coronary syndrome alter the expression and protein concentration of platelet surface receptors such as P2Y12 compared to healthy controls?
Effect estimate: 2.44-fold increase (95% CI 1.73-3.42)
p-value: p=<0.0001
ACS patients exhibit significant upregulation of key platelet surface receptors, particularly P2Y12, at both the mRNA and protein levels, providing insights into the molecular basis of platelet hyperreactivity.
May support platelet hyperreactivity mechanisms in ACS; hypothesis-generating and requires prospective validation before clinical use.
The pathological conditions caused by blood platelet activation constitute a fundamental core in the pathogenesis of Acute Coronary Syndrome (ACS). The hyperactivity of platelets in ACS is well-documented, but there is still little research into the molecular basis of phenotypic changes in platelet functionality. To expand the knowledge of this phenomenon, we analyzed the disturbances in the expression of several key platelet receptors and the aspect of regulating potential abnormalities. Platelet surface receptors are responsible for maintaining the hemostatic balance, platelet interaction with immune cells, and support of the coagulation cascade leading to occlusion of the vessel lumen. Due to their prominent role, platelet receptors constitute a major target in pharmacological treatment. Our work aimed to identify the molecular alteration of platelet surface receptors, which showed augmented mRNA expression of P2Y12, GP1BB, ITGA2B, and ITGB3 and increased protein concentrations of P2Y12 and GP IIb/IIIa in ACS. The upregulation of the P2Y12 level was also confirmed by confocal and cytometric visualization. Furthermore, we evaluated the expression of two microRNAs: miR-223-3p and miR-126-3p, which were suggested to regulate platelet P2Y12 expression. Results of our study present new insight into the molecular background of ACS.
No takes yet. Share an insight, caveat, or question.
Szelenberger et al. (2022) conducted a case-control in Acute Coronary Syndrome. Acute Coronary Syndrome vs. Healthy controls was evaluated on P2Y12 mRNA expression (2.44-fold increase, 95% CI 1.73-3.42, p=<0.0001). Acute coronary syndrome was associated with a 2.44-fold increase in platelet P2Y12 mRNA expression compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: